- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Replimune Group Inc RP1 Program Update Call TranscriptDec 05, 2023
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Replimune Group Inc to Host Virtual Investor Event TranscriptDec 07, 2022
- Replimune Group Inc To Host Investor Day TranscriptMar 30, 2022
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Replimune Group Inc Annual Shareholders Meeting TranscriptSep 08, 2021
- Replimune Group Inc Virtual Investor Event Corporate Call TranscriptJun 03, 2021
- Replimune Group Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Replimune Group Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Replimune Group Inc to Provide Phase 1/2 Clinical Data Update on Patients with Melanoma and Non-Melanoma Skin Cancers - Conference Call TranscriptJun 03, 2020
- Replimune Group Inc at JPMorgan Healthcare Conference TranscriptJan 15, 2020
Replimune Group Inc to Provide Phase 1/2 Clinical Data Update on Patients with Melanoma and Non-Melanoma Skin Cancers - Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Replimune RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer Investor Event. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, to Philip Astley-Sparke, CEO. Thank you. Please go ahead, sir.
Good morning, and thank you for joining our midyear data update event. And before we begin, I need to highlight our forward-looking statements. I am Philip Astley-Sparke, CEO of Replimune, and I have with me today, Dr. Robert Coffin, our President and Chief R&D Officer.
We also have Dr. Kevin Harrington, Professor in Biological Cancer Therapies at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden. Dr. Harrington will describe some of his experiences of treating his patients with cutaneous squamous-cell carcinoma with RP1 combined
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)